Clinical trial PRECISION 2
Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes (PRECISION 2)
| Organ | Multiple |
|---|---|
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Oui |
| Sponsor | BSMO |
| EudraCT Identifier | 2018-00296637 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03967938 |
| Inclusion criteria | Homologous recombination deficiency |
| Last update |